> For Research Use Only. VIP (Vasoactive Intestinal Peptide) as a synthetic research peptide is not approved by the FDA for self-administration. Aviptadil (a synthetic VIP analog) has received regulatory authorization in specific clinical contexts; its use is limited to licensed medical and research settings. This article is intended for researchers and educators only.
---
Introduction
Vasoactive Intestinal Peptide (VIP) is a 28-amino-acid neuropeptide with one of the most remarkable tissue distribution profiles in the human body. First isolated from porcine intestinal tissue in 1970 by Said and Mutt, VIP was initially classified as a gut hormone for its role in smooth muscle relaxation and intestinal secretion. Subsequent decades of research revealed that VIP is simultaneously a gut peptide, a central and peripheral neurotransmitter, a circadian clock modulator in the suprachiasmatic nucleus (SCN), and a potent anti-inflammatory immunomodulatory signal.
This extraordinary breadth — from gut motility to circadian timing to autoimmune regulation — explains why VIP appears across such diverse research domains, from inflammatory bowel disease to pulmonary arterial hypertension to COVID-19 acute respiratory failure. The peptide sequence HSDAVFTDNYTRLRKQMAVKKYLNSILN is structurally related to glucagon, secretin, and PACAP (pituitary adenylate cyclase-activating peptide), reflecting shared evolutionary origins in the glucagon superfamily.
Aviptadil, the synthetic form of human VIP, achieved regulatory approval for pulmonary arterial hypertension (PAH) in some jurisdictions and Emergency Use Authorization (EUA) for COVID-19 ARDS in 2020. These approvals brought human safety and pharmacokinetic data into the research literature, substantially advancing the translational picture of VIP biology.
---
Mechanism of Action: VPAC1 and VPAC2 Receptor Biology
VIP acts through two primary receptors: VPAC1 (VIPR1) and VPAC2 (VIPR2), both class B GPCRs that signal primarily through Gs to increase intracellular cAMP. Both receptors bind VIP and PACAP with similar affinity; VPAC1 also has high affinity for secretin, while VPAC2 is slightly more selective for PACAP-27.
Tissue distribution creates functional specificity:
- •Lungs: VPAC1 and VPAC2 expressed on bronchial smooth muscle, type II pneumocytes, and pulmonary vascular endothelium. VIP relaxes pulmonary vasculature and promotes surfactant production — the basis for its use in PAH.
- •Immune cells: VPAC1 is the primary receptor on T lymphocytes, monocytes, dendritic cells, and macrophages. cAMP elevation in immune cells shifts cytokine profiles from pro-inflammatory (TNF-α, IL-6, IL-12) to anti-inflammatory (IL-10, TGF-β), polarizes macrophages toward M2 phenotype, and promotes T regulatory (Treg) cell differentiation.
- •Suprachiasmatic nucleus (SCN): VPAC2 is essential for circadian pacemaker function. VIPergic neurons within the SCN synchronize the heterogeneous population of circadian clock neurons by coordinating their cAMP oscillations — a kind of biochemical social network that keeps the brain's master clock coherent.
- •Enteric nervous system: Dense VIPergic innervation of the gut wall; VIP acts as an inhibitory neurotransmitter relaxing longitudinal muscle while stimulating Cl− and water secretion from enterocytes via cAMP.
- •Peripheral nervous system: VIP is co-released with acetylcholine from parasympathetic terminals, modulating vasodilation (especially in salivary glands, the cerebral circulation, and sexual arousal tissues).
The cAMP-PKA-CREB axis downstream of VPAC activation mediates most of VIP's effects, though GI targets also use cAMP-independent pathways. PKA phosphorylates CLOCK/BMAL1 complex components in SCN neurons, synchronizing circadian gene expression rhythms.
---
Key Research Findings
1. VIP as the Master Synchronizer of the SCN Circadian Clock (Aton & Colwell, 2005)
This landmark study demonstrated that VIP, released from SCN neurons in a circadian pattern, is essential for synchronizing individual clock neurons into a coherent ensemble. Using VIP knockout and VPAC2 knockout mice, Aton and Colwell showed that loss of VIP signaling produced desynchronized, dampened rhythms at the population level — even though individual clock neurons retained molecular oscillations. VIP is now understood as the "social coordinator" of the circadian network, broadcasting phase information that keeps divergent cellular clocks aligned. [PMID: 15750589]
2. VIP Receptor Pharmacology: VPAC1, VPAC2, and Drug Design (Harmar et al., 2012)
A comprehensive pharmacological review from the NC-IUPHAR Committee established the canonical binding affinities, G protein coupling profiles, and tissue distribution of VPAC1 and VPAC2. Key findings: VPAC1 couples more efficiently to Gi in some immune cell types, adding a layer of context-dependent signaling not captured by classic Gs models; VPAC2 shows higher expression in the SCN and pancreas; both receptors undergo rapid internalization upon VIP binding, complicating sustained-dosing pharmacology. This paper is the definitive pharmacological reference for VIP receptor research. [PMID: 22289055]
3. Class B GPCR Structural Pharmacology Basis (Laburthe & Couvineau, 2007)
Structural studies of VPAC receptors identified the large N-terminal extracellular domain as the primary site of VIP binding, with the transmembrane domain required for G protein coupling — a two-domain binding mechanism distinct from family A GPCRs. Mutations in the N-terminal domain selectively impair VIP binding without affecting PACAP-27 binding, providing a structural basis for designing VPAC1-selective vs. VPAC2-selective agonists and antagonists. [PMID: 17574305]
4. Aviptadil (IV VIP) in Critical COVID-19 Respiratory Failure (Youssef et al., 2022)
This Phase 2 trial evaluated IV aviptadil in 196 patients with critical COVID-19 respiratory failure. Patients receiving aviptadil showed significantly higher rates of survival to hospital discharge and recovery from respiratory failure vs. controls. The proposed mechanism involves VIP's known role as a pulmonary vasoprotective agent: VPAC1-mediated suppression of cytokine storm (reducing IL-6, TNF-α), protection of type II pneumocytes from SARS-CoV-2-induced apoptosis, and attenuation of pulmonary vascular constriction. The study positioned aviptadil as a lung-protective agent targeting the immunopathological component of severe COVID-19. [PMID: 36044317]
5. VIP as Immunomodulator in Allergic and Inflammatory Disease (Verma & Manohar, 2017)
This review catalogued VIP's anti-inflammatory effects across allergy, asthma, and atopic disease models. VIPergic nerve fibers are prominent in airway mucosa; their density is reduced in allergic asthma, suggesting that VIP deficiency may contribute to airway hyperresponsiveness. VIP administration suppresses mast cell degranulation, eosinophil chemotaxis, and IgE-driven immune activation in rodent models. The authors proposed VIP-based therapeutics as a strategy for Type 2 inflammatory disorders — an area now seeing clinical investigation. [PMID: 28964637]
---
Research Applications
VIP research spans an unusually wide set of domains:
Circadian Biology: VIP and VPAC2 knockout mice are standard models for studying circadian coherence, sleep-wake cycle disruption, and the consequences of circadian desynchrony (metabolic syndrome, immune dysregulation).
Pulmonary Arterial Hypertension: VIPergic nerve supply is lost in PAH patient lung tissue; aviptadil (inhaled or IV) is evaluated for its vasodilatory and anti-remodeling effects in PAH.
Inflammatory and Autoimmune Disease: VIP peptides and VPAC1 agonists are studied as immunomodulators in models of rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.
COVID-19 and ARDS: Aviptadil trials initiated during the pandemic generated novel human data on VIP's lung-protective and anti-cytokine mechanisms.
Neurology: VIP modulates anxiety behavior, pain signaling, and hippocampal neurogenesis; VPAC2 polymorphisms are associated with schizophrenia risk.
Reproductive Biology: VIP is secreted from the uterus and plays roles in embryo implantation and decidualization.
Common models: VPAC2 knockout mice (circadian), VIP knockout mice, Lewis rat (autoimmune), C57BL/6 (metabolic), A549 human lung cells, PBMC cultures (immune).
---
Safety & Limitations
Aviptadil, the synthetic VIP analog used in clinical trials, has a generally favorable short-term safety profile in critical care contexts. Key considerations:
- •Blood pressure: The "vasoactive" in VIP's name is real — high-dose VIP produces dose-dependent vasodilation and hypotension; blood pressure monitoring is required in parenteral research protocols.
- •Short half-life: Endogenous VIP is cleared in minutes; aviptadil clinical protocols use continuous infusion to maintain therapeutic levels.
- •VPAC subtype selectivity: Many commercially available VIP research peptides activate both VPAC1 and VPAC2; researchers needing subtype selectivity must use synthetic analogs specifically designed for selectivity.
- •Sex differences: VPAC2 expression in the SCN shows sex differences; female rodents show more pronounced circadian responses to VIP manipulation than males.
- •Dose-response complexity: VIP exhibits biphasic dose-response curves in some immune cell types (low doses stimulatory, high doses suppressive for certain cytokines), complicating dose selection in immunological research.
---
Sourcing on Peptides.SO
Researchers can compare VIP supplier listings on Peptides.SO's VIP page, with 33+ suppliers as of 2026. For circadian biology and SCN electrophysiology experiments, high-purity (>98% HPLC) synthetic VIP is essential; the platform's purity-filter tools assist in identifying suppliers meeting this threshold. For immunological studies, endotoxin content certification is an additional quality criterion to verify.
Related research profiles: PACAP Research Profile, Secretin Research Profile.
---
References
1. Aton SJ, Colwell CS, Harmar AJ, Waschek J, Herzog ED. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005;8(4):476–483. PMID: 15750589. DOI: 10.1038/nn1419
2. Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Br J Pharmacol. 2012;166(1):4–17. PMID: 22289055. DOI: 10.1111/j.1476-5381.2012.01871.x
3. Laburthe M, Couvineau A. Molecular pharmacology and structure of VPAC Receptors for VIP and PACAP. Regul Pept. 2007;137(1–2):55–63. PMID: 17574305. DOI: 10.1016/j.regpep.2006.12.001
4. Youssef JG, Lavin P, Barnes S, et al. Efficacy of Aviptadil for Treatment of Critical COVID-19: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Adaptive Trial. Crit Care. 2022;26(1):249. PMID: 36044317. DOI: 10.1186/s13054-022-04095-y
5. Verma AK, Manohar M, Upparahalli Venkateshaiah S, et al. Involuntary role of eosinophils and mast cells in VIP-mediated inhibition of chronic inflammation. J Cell Physiol. 2017;234(2):920–928. PMID: 28964637. DOI: 10.1002/jcp.26916